Riximyo®

ACTIVE PRINCIPLE:
rituximab

INDICATION:
Wegener's granulomatosis
microscopic polyangiitis
Rheumatoid Arthritis
Non-Hodgkin lymphoma

DATE:
26/07/2017

STATUS:
Authorized

MORE INFORMATION